Tuesday, January 10, 2017 12:56:16 AM
It looks like the NR patent-holder's (Charles Brenner) student's (Samuel Trammell) U of Iowa PhD thesis sheds some light on the issue in mouse livers in Chapter 5, recently published in Nature Communications here:
http://www.nature.com/articles/ncomms12948
185 mg/kg NR was given to mice orally (7 doses over 12 hours), along with equimolar doses of NA and NAM. Figure 5b shows that NR increased mouse liver NAD+ levels with an AUC of ~16,000, significantly more than NA (AUC ~8,000) and slightly more (not significantly so) as NAM (AUC ~14,000).
One could perhaps conclude that in mice, NR is 2x as effective at increasing liver NAD+ vs NA, and ~15% more effective than NAM. In general, mice started with around ~1 mM NAD+. This increased to ~2 mM NAD+ with NA, a peak of ~3 mM NAD+ with NAM, and to >4 mM NAD+ peak with NR.
It's interesting that NR did not increase NAD+ levels significantly in the mouse heart (but it did increase NMN and NAM in heart).
They used a mouse dose of 185 mg/kg to match approximately the human dose given - 1000 mg (to a 66.5 kg, 52 yo male - Dr. Brenner? born in 1961), using mouse to human conversion factor of 12.3 based on BSA.
Apparently recommended daily dose of Vitamin B3 as NA or NAM is 15 mg /day to prevent pellagra. They say the equivalent dose of NR would be 35.7 mg (not sure on that conversion). The study tested humans with 100, 300, or 1000 mg doses of NR, and measured NAD+ increases in human blood cells (N=12). Figure 8b shows that NR increased concentrations from ~12 uM to slightly above that, say ~16 uM at 100 mg, and to ~18 uM at 300 or 1000 mg. Quantitatively, the NAD+ increase was dose dependent, with huge amount of variability between subjects.
I believe the larger Elysium study (N=120, 10x larger) showed that 250 mg/day supplementation in 60-80 year olds increased blood NAD+ levels 40% and 500 mg/day 80% over 4-8 weeks. Look forward to seeing the details published.
Would love to see the comparison of NA, NAM, and NR in humans in terms of increase in NAD+ in blood and perhaps muscle biopsy (with effects on mitochondrial number). I would be really interested to know what are the NAD+ levels in brain, heart, muscle, blood, and CSF.
One thing to keep in mind is that if NA is 10 times cheaper for equivalent dose of NR, does it really matter if NA is only 1/2 as potent? It would still be 5x better value for increase in NAD+.
There are benefits to avoiding the flushing, for sure. Perhaps the flushing will not allow people to increase their NAD+ levels high enough.
Normal human ageing shows decline in skin tissue NAD+ levels from ~4 mM at age 20, to ~3 at 40, ~2 at 60, and ~1 at 80 years in women, and perhaps worse (lower levels) in men.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0042357
Figure 4.
Another important consideration the SA author brings up besides the 3 vitamins/supplements' effects on NAD+ levels is the NR markup. I recall CDXC charging $1,000/kg or $1/g of NR to Elysium. Other companies then sell say 125 mg x60 pills = 7.5 g for $40, a ~5x markup! Maybe CDXC could sell direct to consumer to cut out the middle man?
I remain long CDXC. I think this is another overreaction, and that NR will show to be an important neuroprotectant and anti-aging supplement/medicine.
Recent CDXC News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 12:32:40 PM
- ChromaDex Appoints Ozan Pamir as Chief Financial Officer • Business Wire • 09/20/2024 12:32:00 PM
- ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics • Business Wire • 09/10/2024 12:32:00 PM
- ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions • Business Wire • 09/09/2024 12:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 11:06:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/23/2024 03:52:27 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024 • Business Wire • 08/23/2024 12:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:15:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:15:03 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/21/2024 10:06:58 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/21/2024 10:05:57 AM
- ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+ • Business Wire • 08/19/2024 12:32:00 PM
- ChromaDex Corporation Reports Second Quarter 2024 Financial Results • Business Wire • 08/07/2024 08:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:02:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:01:36 PM
- ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference • Business Wire • 08/05/2024 12:32:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 08:52:56 PM
- ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 • Business Wire • 07/24/2024 12:34:00 PM
- ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) • Business Wire • 07/23/2024 12:32:00 PM
- ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel • Business Wire • 07/22/2024 12:34:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:00:18 PM
- ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August • Business Wire • 07/16/2024 12:34:00 PM
- ChromaDex to Join Russell 2000® Index • Business Wire • 07/01/2024 12:32:00 PM
- Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) • Business Wire • 06/24/2024 12:32:00 PM
- ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) • Business Wire • 06/13/2024 12:32:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM